Custom Antibody Market Size Worth USD 984.3 Million in 2030 | Emergen Research

The global custom antibody market size is expected to reach USD 984.3 Million in 2030 and register a steady revenue CAGR of 10.6% over the forecast period, according to latest analysis by Emergen Research. This can be attributed to the increasing demand for antibody-based therapeutics from both pharmaceutical and biotechnology companies. The report further mentions that the market is being driven by the development of novel antibody therapeutics for cancer and other chronic diseases, as well as the introduction of innovative technologies such as monoclonal antibodies (mAbs), phage display, and transgenic animals.

Monoclonal antibodies are made by fusing a cancer cell with a healthy mouse cell. This produces an immortal hybrid cell that can create large quantities of the same antibody. Polyclonal antibodies are made by injecting an animal with a foreign substance and then collecting the antibodies that the animal produces in response. Custom antibody services can generate monoclonal or polyclonal antibodies to customer specifications.

Antibodies can be created artificially for research or therapeutic purposes. A number of companies offer custom antibody services to generate monoclonal or polyclonal antibodies to customer specifications. There are a number of companies that offer custom antibody services. These companies use a variety of methods to generate monoclonal or polyclonal antibodies to customer specifications. Custom antibody services can be used to generate antibodies for research or therapeutic purposes. As the demand for these services rises, the custom antibody market is expected to grow. Many illnesses, including some forms of cancer, are treated with antibodies. The development of new therapeutic antibodies is a major focus of the pharmaceutical industry. In addition, research into the function of various proteins in the body often requires the use of artificial antibodies.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @

The ADC is a revolutionary treatment approach that offers the unique ability to target cancer cells with high specificity and potency while minimizing exposure of healthy tissues to the therapeutic agents. ADCs are composed of an antibody linked to a small molecule drug via a stable chemical bond. The ADC is designed to bind to a specific cell surface protein expressed on tumor cells and internalize upon binding. Once inside the cell, the ADC is designed to release its cytotoxic drug payload, resulting in cell death.

The key advantages of ADCs over conventional small molecule drugs and monoclonal antibodies (mAbs) are their ability to specifically target cancer cells and deliver a potent cytotoxic payload directly to the site of the tumor. ADCs offer the potential to improve clinical outcomes and reduce treatment-related side effects by specifically targeting cancer cells while sparing healthy tissues.

Some Key Highlights From the Report

  • On 14 July 2022, Bio-Rad Laboratories, Inc. announced the launch of its new line of custom antibodies, which are designed to target specific proteins and antigens. The new line of products includes monoclonal, polyclonal, and recombinant antibodies, which can be used for a variety of applications, including ELISA, Western blotting, immunohistochemistry, and flow cytometry.
  • Antibody development segment is expected to experience highest growth during the forecast period due to the expansion of biopharmaceutical and biotechnology companies. Also, the increase in research and development activities for the development of therapeutic antibodies is projected to boost market growth during the forecast period.
  • The monoclonal antibodies segment is expected to account for a large revenue share in the global market over the forecast period owing to several advantages associated with them including the ability to bind a single epitope, high specificity and affinity for the target antigen, and low immunogenicity.
  • In terms of revenue, the therapeutic antibody segment is expected to grow at the fastest rate over the forecast period. This growth can be attributed to the increasing use of therapeutic antibodies for the treatment of cancer and other chronic diseases such as autoimmune disorders, infectious diseases, and cardiovascular diseases. Moreover, the increasing investment by pharmaceutical and biotechnology companies in the development of novel antibody therapeutics is also driving the growth of this segment.
  • The hospital pharmacies segment is expected to grow at the fastest rate over the forecast period. This growth can be attributed to the increasing number of hospitals and clinics, which are adopting custom antibody products for the treatment of various diseases. Moreover, the availability of skilled professionals and technicians in hospital pharmacies is also driving the growth of this segment.
  • Some major companies in the global market report include Thermo Fisher Scientific Inc., GenScript, Abcam plc, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., BioLegend, Inc., Rockland Immunochemicals. Inc., ProMab.
  • The North America region is projected to dominate the global market for custom antibodies over the forecast period. This is due to growing demand from biotechnology and pharmaceutical companies in the region. Also, the region has a large number of clinical research organizations that are involved in the development of new therapeutic antibodies.
  • The Asia Pacific region is expected to grow at the highest CAGR during the forecast period. This is due to factors such as growing biotechnology and pharmaceutical industries in the region. Also, the increasing investment by government and private companies in research and development activities is expected to fuel the growth of the market in the region.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@

Emergen Research has segmented the global custom antibody market on the basis of service, type, source, end-use, and region:

  • Service Outlook (Revenue, USD Billion; 2019-2030)
    • Antibody Development
      1. Antibody Characterization
      2. Antigen Preparation
      3. Immunization & Hybridoma Production
    • Antibody Production & Purification
    • Antibody Fragmentation & Labeling
  • Type Outlook (Revenue, USD Billion; 2019-2030)
    • Monoclonal Antibodies
    • Polyclonal Antibodies
    • Recombinant Antibodies
    • Other Custom Antibodies
  • Source Outlook (Revenue, USD Billion; 2019-2030)
    • Mice
    • Rabbits
    • Other Sources
  • End-Use Outlook (Revenue, USD Billion; 2019-2030)
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • Contract Research Organizations
  • Regional Outlook (Revenue, USD Billion; 2019-2030)
    • North America
      1. U.S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Sweden
      7. BENELUX
      8. Rest of Europe
    • Asia Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. UAE
      3. South Africa
      4. Israel
      5. Rest of MEA

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @

Explore More Reports Emergen Research:

Healthcare Cloud Computing Market

Li-Fi Market

Contact Lenses Market

Eubiotics Market

Structured Cabling Market

Collagen Peptides Market

Feldspar Market

Food-Grade Gases Market

IR Spectroscopy Market

Cognitive Assessment and Training Market

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756


Emergen Research Media Citations:

Visit for More Insights:

Explore Our Custom Intelligence services | Growth Consulting Services

Press Release Available @



Back to news